Fatigue News and Research

RSS

Researchers develop blue light to help manage internal clocks of night workers

Researchers at Universit- Laval have developed a blue light to help bleary eyed shift workers regulate their internal clocks and get the sleep they need when they need it.

2 Aug 2012

Sickle cell trait link with sudden athlete death ‘confirmed’

Researchers say they have definitively confirmed that there is a link between the sickle cell trait and sudden cardiac death in African–American athletes.

2 Aug 2012

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Breast cancer is the most important cancer for women in the developed world. About 20% of all patients diagnosed with breast cancer die of metastatic disease.

1 Aug 2012

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.

30 Jul 2012

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Scientists at the National Institutes of Health have identified several factors in people infected with the hepatitis C virus that may predict whether the unusually rapid progression of disease from initial infection to severe liver conditions, such as cirrhosis, will occur. Knowing whether a patient's condition is likely to deteriorate quickly could help physicians decide on the best course of treatment.

27 Jul 2012

Surgical distractions could have disastrous consequences

In a simulated study, the rate of major errors committed while novice surgeons were exposed to typical interruptions and distractions was almost 50%, indicating that such exposure could seriously risk patient safety.

26 Jul 2012

Myotonia less important to patients with myotonic dystrophy than other symptoms

Complex, multi-system diseases like myotonic dystrophy - the most common adult form of muscular dystrophy - require physicians and patients to identify which symptoms impact quality of life and, consequently, what treatments should take priority. However, a new study out this month in the journal Neurology reveals that there is often a disconnect between the two groups over which symptoms are more important, a phenomenon that not only impacts care but also the direction of research into new therapies.

26 Jul 2012

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal.

26 Jul 2012

Study uses photodynamic therapy to ablate cardiac myocytes responsible for arrhythmias

University of Michigan heart researchers are shedding light on a safer method for steadying an abnormal heart rhythm that prevents collateral damage to healthy cells.

25 Jul 2012

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Pfizer Inc. announced today that top-line results for Lyrica (pregabalin) capsules Study A0081147 - Long Term Safety and Efficacy of Pregabalin in Subjects with Generalized Anxiety Disorder (GAD) - demonstrate that drug discontinuation symptoms were low after tapering Lyrica treatment following three months and six months in GAD patients.

23 Jul 2012

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

The U.S. Food and Drug Administration today approved Kyprolis (carfilzomib) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy. A form of blood cancer that arises from plasma cells, multiple myeloma usually grows in bone marrow, the soft, spongy tissue found inside most bones.

21 Jul 2012

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

Ligand Pharmaceuticals Incorporated today announced that its licensee, Onyx Pharmaceuticals, received accelerated approval from the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection, a proteasome inhibitor indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

21 Jul 2012

Fatigue News and Research

Researchers develop blue light to help manage internal clocks of night workers

Sickle cell trait link with sudden athlete death ‘confirmed’

Breast cancer drug bevacizumab (Avastin): an interview with Dr Anna Dorothea Wagner

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Viral evolution and host protein levels predict rapid disease progression in hepatitis C patients

Surgical distractions could have disastrous consequences

Myotonia less important to patients with myotonic dystrophy than other symptoms

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Study uses photodynamic therapy to ablate cardiac myocytes responsible for arrhythmias

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

Choir participation improves quality of life factors for cancer survivors and their carers

Unexplained fatigue in women: start iron supplements

Non-motor Parkinson’s disease symptoms show variable course

Iron deficiency in women ‘may be under-recognized’

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Police officers with sleep deprivation more susceptible to chronic fatigue and health problems

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News